PolymarketGeschlossenVerfügbarkeit prüfenKein KYC2% GebührVerifizierte AuflösungsdatenOrdentlich kalibriertDieser Markt wurde entschieden: Yes
Entschieden: 28.06.2026, 23:21
Vom Anbieter verifizierte Auflösung
CoinRithm hat anbietergestützte Nachweise für Gewinner und Auflösungszeit dieses Marktes.
Gewinnausgang
Yes
7 Tage vorher
—
24 Stunden vorher
—
Aktuelle implizite Wahrscheinlichkeit
Ja 100%+0.0pt
Marktqualitat
≤49 / 100
Niedrige Qualität24h-Volumen
4830,5 €
Liquidität
—
Liquidität unbekanntGeld / Brief
99.9% / 100.0%
Spread
0.1 pt
Enger Spread7d-Änderung
+26.9 pts
Marktdaten
Aktualisiert vor 64 Tagen
Veraltet4. Juni 26, 19:5430. Juni 26, 0:00
Wahrscheinlichkeitsverlauf
No0%
Yes100%
100%
0%
Regeln
As of market creation, the FDA's expected decision date for the specified application is June 30, 2026.
- This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Viridian Therapeutics's Veligrotug as a treatment for thyroid eye disease by July 14, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
